Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction.

Abstract:

:Quantitative reverse transcription-polymerase chain reaction (RT-PCR) used to detect minor changes in specific mRNA concentrations may be associated with poor reproducibility. Stringent quality control is therefore essential at each step of the protocol, including the PCR procedure. We performed inter-laboratory quality control of quantitative PCR between two independent laboratories, using in-house RT-PCR assays on a series of hormone-related target genes in a retrospective consecutive series of 79 breast tumors. Total RNA was reverse transcribed in a single center. Calibration curves were performed for five target genes (estrogen receptor (ER)alpha, ERbeta, progesterone receptor (PR), CYP19 (aromatase) and Ki 67) and for two reference genes (human acidic ribosomal phosphoprotein PO (RPLPO) and TATA box-binding protein (TBP)). Amplification efficiencies of the calibrator were determined for each run and used to calculate mRNA expression. Correlation coefficients were evaluated for each target and each reference gene. A good correlation was observed for all target and reference genes in both centers using their own protocols and kits (P < 0.0001). The correlation coefficients ranged from 0.90 to 0.98 for the various target genes in the two centers. A good correlation was observed between the level of expression of the ERalpha and the PR transcripts (P < 0.001). A weak inverse correlation was observed in both centers between ERalpha and ERbeta levels, but only when TBP was the reference gene. No other correlation was observed with other parameters. Real-time PCR assays allow convenient quantification of target mRNA transcripts and quantification of target-derived nucleic acids in clinical specimens. This study addresses the importance of inter-laboratory quality controls for the use of a panel of real-time PCR assays devoted to clinical samples and protocols and to ensure their appropriate accuracy. This can also facilitate exchanges and multicenter comparison of data.

journal_name

Endocr Relat Cancer

journal_title

Endocrine-related cancer

authors

de Cremoux P,Bieche I,Tran-Perennou C,Vignaud S,Boudou E,Asselain B,Lidereau R,Magdelénat H,Becette V,Sigal-Zafrani B,Spyratos F

doi

10.1677/erc.1.00808

subject

Has Abstract

pub_date

2004-09-01 00:00:00

pages

489-95

issue

3

eissn

1351-0088

issn

1479-6821

journal_volume

11

pub_type

杂志文章
  • LDLR-mediated lipidome-transcriptome reprogramming in cisplatin insensitivity.

    abstract::Platinum-based therapy remains the cornerstone for cancer therapy; however, its efficacy varies. The role of lipoprotein receptor-mediated lipid entry for cancer development has been reported. Yet, the roles and mechanism of the low-density lipoprotein receptor (LDLR) in chemo-sensitivities are unknown. In the current...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0095

    authors: Chang WC,Wang HC,Cheng WC,Yang JC,Chung WM,Ho YP,Chen L,Hung YC,Ma WL

    更新日期:2020-02-01 00:00:00

  • Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity.

    abstract::Somatostatin-producing neuroendocrine tumors (SOM-NETs) of the duodenum and pancreas appear to be heterogeneous. To determine their clinicopathological profiles, respective data were analyzed on a series of 82 duodenal and 541 pancreatic NETs. In addition, the clinical records of 821 patients with duodenal or pancreat...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1677/ERC-07-0157

    authors: Garbrecht N,Anlauf M,Schmitt A,Henopp T,Sipos B,Raffel A,Eisenberger CF,Knoefel WT,Pavel M,Fottner C,Musholt TJ,Rinke A,Arnold R,Berndt U,Plöckinger U,Wiedenmann B,Moch H,Heitz PU,Komminoth P,Perren A,Klöppel G

    更新日期:2008-03-01 00:00:00

  • Perspectives for immunotherapy in endocrine cancer.

    abstract::The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated signaling cascades within the tumor inaugurated a new era of oncological therapy. Recently, immunotherapy with immune checkpoint inhibitors has started to revolut...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-16-0169

    authors: Latteyer S,Tiedje V,Schilling B,Führer D

    更新日期:2016-10-01 00:00:00

  • Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells.

    abstract::Pancreatic endocrine tumours (PETs) are rare and 'indolent' neoplasms that usually develop metastatic lesions and exhibit poor response to standard medical treatments. Few studies have investigated pathways responsible for PET cell growth and invasion and no alternative therapeutic strategies have been proposed. In a ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01318

    authors: Di Florio A,Capurso G,Milione M,Panzuto F,Geremia R,Delle Fave G,Sette C

    更新日期:2007-03-01 00:00:00

  • Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors.

    abstract::Pancreatic neuroendocrine tumors (PanNETs) are rare in von Hippel-Lindau disease (VHL) but cause serious morbidity and mortality. Management guidelines for VHL-PanNETs continue to be based on limited evidence, and survival data to guide surgical management are lacking. We established the European-American-Asian-VHL-Pa...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0100

    authors: Krauss T,Ferrara AM,Links TP,Wellner U,Bancos I,Kvachenyuk A,Villar Gómez de Las Heras K,Yukina MY,Petrov R,Bullivant G,von Duecker L,Jadhav S,Ploeckinger U,Welin S,Schalin-Jäntti C,Gimm O,Pfeifer M,Ngeow J,Hasse-Laza

    更新日期:2018-09-01 00:00:00

  • The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-kit or PDGF-R.

    abstract::Imatinib mesylate (IM), a small molecule that is a selective inhibitor of the ABL, platelet derived growth factor receptor (PDGFR-R) and stem cell ligand receptor (c-kit) tyrosine kinases (TK). IM was also found to inhibit the TK activity of BCR/ABL fusion protein produced in chronic myelogenous leukemia, with marked ...

    journal_title:Endocrine-related cancer

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1677/erc.1.01124

    authors: Gross DJ,Munter G,Bitan M,Siegal T,Gabizon A,Weitzen R,Merimsky O,Ackerstein A,Salmon A,Sella A,Slavin S,Israel Glivec in Solid Tumors Study Group.

    更新日期:2006-06-01 00:00:00

  • Epigenetic regulation by the menin pathway.

    abstract::There is a trend of increasing prevalence of neuroendocrine tumors (NETs), and the inherited multiple endocrine neoplasia type 1 (MEN1) syndrome serves as a genetic model to investigate how NETs develop and the underlying mechanisms. Menin, encoded by the MEN1 gene, at least partly acts as a scaffold protein by intera...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-17-0298

    authors: Feng Z,Ma J,Hua X

    更新日期:2017-10-01 00:00:00

  • Inhibition of Notch signaling attenuates pituitary adenoma growth in Nude mice.

    abstract::Preclinical and clinical studies support that Notch signaling may play an important oncogenic role in cancer, but there is scarce information for pituitary tumors. We therefore undertook a functional study to evaluate Notch participation in pituitary adenoma growth. Tumors generated in Nude mice by subcutaneous GH3 so...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-18-0337

    authors: Zubeldía-Brenner L,De Winne C,Perrone S,Rodríguez-Seguí SA,Willems C,Ornstein AM,Lacau-Mengido I,Vankelecom H,Cristina C,Becu-Villalobos D

    更新日期:2019-01-01 00:00:00

  • Multiple endocrine neoplasia type 1.

    abstract::Combined clinical and laboratory investigations of multiple endocrine neoplasia type 1 (MEN1) have resulted in an increased understanding of this disorder which may be inherited as an autosomal dominant condition. Defining the features of each disease manifestation in MEN1 has improved patient management and treatment...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060449

    authors: Pannett AA,Thakker RV

    更新日期:1999-12-01 00:00:00

  • Aromatase inhibitors and their antitumor effects in model systems.

    abstract::The potential of aromatase (estrogen synthetase) within the breast to provide a significant source of estrogen mediating tumor proliferation is suggested by studies reporting 4- to 6-fold higher estrogen levels in tumors than in plasma of postmenopausal patients with breast cancer. Recent studies in our laboratory hav...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.0.0060205

    authors: Brodie A,Lu Q,Liu Y,Long B

    更新日期:1999-06-01 00:00:00

  • The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.

    abstract::Experimental models of neuroendocrine tumour disease are scarce, and no comprehensive characterisation of existing gastroenteropancreatic neuroendocrine tumour (GEPNET) cell lines has been reported. In this study, we aimed to define the molecular characteristics and therapeutic sensitivity of these cell lines. We ther...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0445

    authors: Hofving T,Arvidsson Y,Almobarak B,Inge L,Pfragner R,Persson M,Stenman G,Kristiansson E,Johanson V,Nilsson O

    更新日期:2018-03-01 00:00:00

  • Differential sensitivities to lactate transport inhibitors of breast cancer cell lines.

    abstract::The tumour microenvironment is known to be acidic due to high glycolytic rates of tumour cells. Monocarboxylate transporters (MCTs) play a role in extracellular acidification, which is widely known to be involved in tumour progression. Recently, we have described the upregulation of MCT1 in breast carcinomas and its a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-13-0132

    authors: Morais-Santos F,Miranda-Gonçalves V,Pinheiro S,Vieira AF,Paredes J,Schmitt FC,Baltazar F,Pinheiro C

    更新日期:2013-12-16 00:00:00

  • Factors regulating the growth of metastatic cancer in bone.

    abstract::Metastatic tumor cells can interfere directly with the function of bone cells involved in normal bone remodeling or indirectly by influencing the behavior of hematopoietic, stromal and other cells in bone marrow that interact with bone cells. Recent studies of metastatic cancer have revealed that tumor cells interact ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060333

    authors: Boyce BF,Yoneda T,Guise TA

    更新日期:1999-09-01 00:00:00

  • Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.

    abstract::To analyze the genetic alterations of pheochromocytomas and evaluate the difference among malignant, extra-adrenal, and benign pheochromocytomas. Forty-three tumor samples were tested for genetic changes using multiplex ligation-dependent probe amplification. Among them, 39 samples were available for protein expressio...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/ERC-07-0188

    authors: Yuan W,Wang W,Cui B,Su T,Ge Y,Jiang L,Zhou W,Ning G

    更新日期:2008-03-01 00:00:00

  • Pathways of chemotherapy resistance in castration-resistant prostate cancer.

    abstract::Chemotherapy remains the major treatment option for castration-resistant prostate cancer (CRPC) and limited cytotoxic options are available. Inherent chemotherapy resistance occurs in half of all patients and inevitably develops even in those who initially respond. Docetaxel has been the mainstay of therapy for 6 year...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-10-0343

    authors: Mahon KL,Henshall SM,Sutherland RL,Horvath LG

    更新日期:2011-07-04 00:00:00

  • Overexpression of the natural antisense hypoxia-inducible factor-1alpha transcript is associated with malignant pheochromocytoma/paraganglioma.

    abstract::Paragangliomas (PGLs) have widely different metastastic potentials. Two different types of PGLs can be defined by expression profiling. Cluster 1 PGLs exhibit VHL and/or succinate dehydrogenase (SDH) mutations and a pseudohypoxic phenotype. RET and neurofibromatosis type 1 (NF1) mutations occur in cluster 2 tumors cha...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-10-0184

    authors: Span PN,Rao JU,Oude Ophuis SB,Lenders JW,Sweep FC,Wesseling P,Kusters B,van Nederveen FH,de Krijger RR,Hermus AR,Timmers HJ

    更新日期:2011-04-28 00:00:00

  • Thyrotoxicosis with concomitant thyroid cancer.

    abstract::Thyrotoxicosis with concomitant thyroid cancer is rare and poorly recognized, which may result in delayed diagnosis, inappropriate treatment and even poor prognosis. To provide a comprehensive guidance for clinicians, the etiology, pathogenesis, diagnosis and treatment of this challenging setting were systematically r...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0129

    authors: Fu H,Cheng L,Jin Y,Chen L

    更新日期:2019-07-01 00:00:00

  • Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.

    abstract::The function of estrogen receptor beta (ER-beta) in mammary tissue is not completely understood. While early observations were often conflicting, more recent data suggest an important role as a tumor-suppressor gene. A decrease of ER-beta expression has been observed in ductal carcinoma in situ and invasive carcinoma ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1677/erc.1.01088

    authors: Rody A,Holtrich U,Solbach C,Kourtis K,von Minckwitz G,Engels K,Kissler S,Gätje R,Karn T,Kaufmann M

    更新日期:2005-12-01 00:00:00

  • The optimal imaging of adrenal tumours: a comparison of different methods.

    abstract::Computed tomography (CT; unenhanced, followed by contrast-enhanced examinations) is the cornerstone of imaging of adrenal tumours. Attenuation values of <10 Hounsfield units on an unenhanced CT are practically diagnostic for adenomas. When lesions cannot be characterised adequately with CT, magnetic resonance imaging ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/ERC-07-0045

    authors: Ilias I,Sahdev A,Reznek RH,Grossman AB,Pacak K

    更新日期:2007-09-01 00:00:00

  • Aromatase inhibitors in relation to other forms of endocrine therapy for breast cancer.

    abstract::Most endocrine therapies for breast cancer inhibit tumor growth by depriving the cell of estrogen or by blocking its receptor. However, some drugs, such as tamoxifen, can bind to the estrogen receptor (ER) and have both estrogenic and antiestrogenic effects, depending on the tissue, cell, or promoter context. These mi...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0060271

    authors: Osborne CK

    更新日期:1999-06-01 00:00:00

  • Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.

    abstract::Hormonal therapy leads to improved survival in oestrogen receptor (ER) positive early breast cancer and long-term responses in advanced disease. However, resistance to such therapy is a serious clinical problem. This article considers the data for and against there being a significant role for the oncogene HER-2 in su...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1677/erc.0.0080191

    authors: Dowsett M

    更新日期:2001-09-01 00:00:00

  • IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

    abstract::Epidemiologic and experimental evidence suggest that a subset of breast cancer is insulin responsive, but it is unclear whether safe and effective therapies that target the insulin receptor (IR), which is homologous to oncogenes of the tyrosine kinase class, can be developed. We demonstrate that both pharmacologic inh...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0136

    authors: Dool CJ,Mashhedi H,Zakikhani M,David S,Zhao Y,Birman E,Carboni JM,Gottardis M,Blouin MJ,Pollak M

    更新日期:2011-11-14 00:00:00

  • Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival.

    abstract::Obesity increases both the risk and mortality associated with many types of cancer including that of the breast. In mice, obesity increases both incidence of spontaneous tumors and burden of transplanted tumors. Our findings identify leptin, an adipose secreted cytokine, in promoting increased mammary tumor burden in ...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-11-0102

    authors: Zheng Q,Dunlap SM,Zhu J,Downs-Kelly E,Rich J,Hursting SD,Berger NA,Reizes O

    更新日期:2011-07-11 00:00:00

  • The evolving (epi)genetic landscape of pancreatic neuroendocrine tumours.

    abstract::Neuroendocrine neoplasms (NENs) are a relatively rare group of heterogeneous tumours originating from neuroendocrine cells found throughout the body. Pancreatic NENs (PanNENs) are the second most common pancreatic malignancy accounting for 1-3% of all neoplasms developing in the pancreas. Despite having a low backgrou...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-19-0175

    authors: Pipinikas CP,Berner AM,Sposito T,Thirlwell C

    更新日期:2019-08-01 00:00:00

  • Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.

    abstract::Anaplastic thyroid cancer (ATC) is an aggressive malignancy with limited treatment options. We explored novel treatment modalities by targeting epigenetic modifications using inhibitors of BET (e.g. BRD4) activity. We evaluated the efficacy in the treatment of ATC of a novel BET inhibitor, PLX51107 (PLX), currently in...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-19-0107

    authors: Zhu X,Park S,Lee WK,Cheng SY

    更新日期:2019-09-01 00:00:00

  • Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710.

    abstract::The aim of this randomized multicenter phase III trial was to compare chemotherapy and interferon (IFN) in patients with metastatic carcinoid tumors. Patients with documented progressive, unresectable, metastatic carcinoid tumors were randomized between 5-fluorouracil plus streptozotocin (day 1-5) and recombinant IFN-...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1677/ERC-09-0104

    authors: Dahan L,Bonnetain F,Rougier P,Raoul JL,Gamelin E,Etienne PL,Cadiot G,Mitry E,Smith D,Cvitkovic F,Coudert B,Ricard F,Bedenne L,Seitz JF,Fédération Francophone de Cancérologie Digestive (FFCD).,Digestive Tumors Group of the F

    更新日期:2009-12-01 00:00:00

  • Autophagy in endocrine tumors.

    abstract::Autophagy is an important intracellular process involving the degradation of cytoplasmic components. It is involved in both physiological and pathological conditions, including cancer. The role of autophagy in cancer is described as a 'double-edged sword,' a term that reflects its known participation in tumor suppress...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-15-0042

    authors: Weckman A,Rotondo F,Di Ieva A,Syro LV,Butz H,Cusimano MD,Kovacs K

    更新日期:2015-08-01 00:00:00

  • CD74 expression and its therapeutic potential in thyroid carcinoma.

    abstract::CD74, the invariant chain of major histocompatibility complex class II, is also a receptor for macrophage migration inhibitory factor (MIF). CD74 and MIF have been associated with tumor progression and metastasis in hematologic and solid tumors. In this study, we found that 60 and 65% of papillary thyroid cancers were...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-14-0269

    authors: Cheng SP,Liu CL,Chen MJ,Chien MN,Leung CH,Lin CH,Hsu YC,Lee JJ

    更新日期:2015-04-01 00:00:00

  • Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer.

    abstract::The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a key signaling pathway that has been linked to both tumorigenesis and resistance to therapy in prostate cancer and other solid tumors. Given the significance of the PI3K/Akt/mTOR pathway in integrating cell survival signals a...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章,评审

    doi:10.1530/ERC-12-0394

    authors: Bitting RL,Armstrong AJ

    更新日期:2013-05-20 00:00:00

  • Combining doxorubicin-nanobubbles and shockwaves for anaplastic thyroid cancer treatment: preclinical study in a xenograft mouse model.

    abstract::Anaplastic thyroid cancer is one of the most lethal diseases, and a curative therapy does not exist. Doxorubicin, the only drug approved for anaplastic thyroid cancer treatment, has a very low response rate and causes numerous side effects among which cardiotoxicity is the most prominent. Thus, doxorubicin delivery to...

    journal_title:Endocrine-related cancer

    pub_type: 杂志文章

    doi:10.1530/ERC-17-0045

    authors: Marano F,Frairia R,Rinella L,Argenziano M,Bussolati B,Grange C,Mastrocola R,Castellano I,Berta L,Cavalli R,Catalano MG

    更新日期:2017-06-01 00:00:00